(2023). Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation. Eclinicalmedicine, 64, 102213. http://doi.org/10.1016/j.eclinm.2023.102213.
(2023). Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK. Bmj, 381, e074678. http://doi.org/10.1136/bmj-2022-074678.
(2022). Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum. Rheumatol Adv Pract, 6, rkac046. http://doi.org/10.1093/rap/rkac046.
(2021). What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?. Rheumatology (Oxford). http://doi.org/10.1093/rheumatology/keab254.
(2021). Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood-tests during long-term treatment: cohort study using data from Clinical Practice Research Datalink Gold and Aurum. Rheumatology (Oxford). http://doi.org/10.1093/rheumatology/keab790.